eligibility_summary
Inclusion: Consent, age 3–70, CD19+ B‑cell lymphoma or R/R CD19+ B‑ALL, measurable/evaluable (Lugano 2014), R/R after ≥2 lines, relapse ≤12 mo post‑ASCT, or per investigator, adequate organs, ECOG 0–1, OS >90d, WOCBP neg β‑hCG, contraception ×1 yr. Exclusion: other active malignancy, recent anti‑cancer tx, CNS disease, WM/POEMS/AL, active HBV/HCV/HIV/CMV/syphilis, severe allergy, major cardiac/systemic/autoimmune/neuro disease, uncontrolled infection, recent surgery/live vaccine, GVHD/immunosuppression, psych/substance issues, pregnancy/lactation/planned conception, investigator unsuitability.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests REVO-UWD-19 (UWD-CD19), an allogeneic, off‑the‑shelf CD19‑targeted CAR‑T cell therapy for relapsed/refractory B‑cell malignancies. Type: biological cell therapy (CAR‑T). Mechanism: donor T cells are engineered with a chimeric antigen receptor to bind CD19 and trigger T‑cell activation and cytotoxic killing of CD19+ B cells, leading to tumor clearance (with expected on‑target B‑cell aplasia). Preconditioning uses fludarabine (purine analog) and cyclophosphamide (alkylating agent) for lymphodepletion to enhance CAR‑T expansion. Targets: CD19 on malignant/normal B cells, host lymphocytes via FC, engages T‑cell cytotoxic pathways. Single infusion, safety/efficacy assessed.